Presentation is loading. Please wait.

Presentation is loading. Please wait.

The Future of Biologics in Part D

Similar presentations


Presentation on theme: "The Future of Biologics in Part D"— Presentation transcript:

1 The Future of Biologics in Part D
Eric Toppy Director of Marketing Strategy Payer, Policy and Emerging Markets Centocor Ortho Biotech Services, LLC

2 Disclaimer The following content and opinions do not necessarily reflect the views and Opinions of Centocor Ortho Biotech Services, LLC

3 Medicare                                                                                                                                        Source: political cartoonist.com

4 Part D- A Success Story Part D Sources: WSJ-July 5, 2005
The Hill. com -Jan 11, 2007

5 Success Defined

6 Success Defined

7 Choice..Choice…Choice

8 Where are they? Source: Kaiser Family Foundation

9 The Gap Source: Kaiser Family Foundation

10 “D” & Impact on Biologics
Sub-Q Growth Accelerated Commoditization Multiple Customer Benefits Consumers Physicians Payers Membership growth Rebate Revenue

11 The “Benefit”

12

13 Donut Hole The “Donut Hole” in Part D is…..
Local establishment where MA-PD enrollment occurs A New diet craze sweeping the nation Patient who pays TROOP of $4,000 Place that most beneficiaries don’t visit due to pressures of competitive marketplace-gap coverage

14 Commercial Part D Programs
Cafeteria Plan Open & Closed Formularies Two Markets Drug Benefit Naïve Part D switch Adverse Selection

15 Biologics & Health Plans
Consumer Choice CMS recommendations Minimal benefit offering P&T Product Review Timing Part B vs. Part D Physician vs. self administered Medical Education Reimbursement CAP Program

16 CMS 2009 Health Plans to post drug formularies
BIO Position- All information that includes step edits, prior authorizations, quantity limits Continuation of Specialty Tiers BIO position- Impact on Patient Affordability Home Health Care Reimbursement 2009

17 Possible Threats to Biologics in Part D
Back to the Future Reduction in Part D payments Elections Reference Pricing BioSimilars Comparative Effectiveness-AHRQ Employer Shift = Increased MLR

18 The Future of Biologics and Part D
Biomarker/Genomics Competing Gov’t needs Reward for Innovation? EMRs Pay for Performance Report Cards Small Molecule Biologics

19 Thank You and Questions


Download ppt "The Future of Biologics in Part D"

Similar presentations


Ads by Google